CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On May 3, 2017, China Biologic Products, Inc. (the Company)
issued a press release announcing its unaudited financial results
for its first quarter ended March 31, 2017. A copy of the press
release, which the Company is furnishing to the Securities and
Exchange Commission, is attached as Exhibit 99.1 and incorporated
by reference herein.
ITEM 7.01 REGULATION FD DISCLOSURE.
The information set forth in Item 2.02 above is incorporated by
reference herein.
The information set forth in Item 2.02 and Item 7.01 of this
Current Report on Form 8-K and Exhibit 99.1 attached hereto shall
not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (Exchange Act), or
otherwise subject to the liabilities of that section, nor shall
such information or such exhibit be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|
Exhibit Number |
Description |
|
| 99.1 | Press release issued by the Company dated May 3, 2017 |
About CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate. CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Recent Trading Information
CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) closed its last trading session up +0.85 at 119.03 with 164,457 shares trading hands.
